| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 324.9 | 311.3 |
| Gross profit | 180.8 | 177.6 |
| Profit before tax | 83.7 | 72.9 |
| Net income | 58.4 | 48.4 |
| EPS (diluted, $ a share) | $0.20 | $0.17 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +20.6% |
|---|---|
| Revenue, year on year | +4.4% |
| Gross margin | 55.6% |
10-Q filed with the SEC, NASDAQ: SHC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Sotera Health Co: key numbers
- Share price
- $16.05Close, Nov 17
- Market cap
- $4.58B
- Shares outstanding
- 285.63MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Misc Health & Allied Services, NECSIC 8090
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Sotera Health Co
All →Sotera Health Financial Results
Sotera Health reported Q3 2026 financial results with net revenues increasing 4.4% to $301 million and net income of $58 million. The company reaffirmed its full-year 2026 outlook for constant currency revenue growth of 5.25% to 6.75% and Adjusted EBITDA growth of 5.75% to 7.25%.
- Term
- Q3 2026
“We are pleased with our third-quarter performance, which included solid top- and bottom-line constant currency growth, along with nearly 100 basis points of sequential Adjusted EBITDA margin expansion.”
Alton Shader, Chief Executive Officer
“Based on our year-to-date performance and expectations for the remainder of the year, we are reaffirming our 2026 constant currency revenue and Adjusted EBITDA outlook.”
Alton Shader, Chief Executive Officer